bluebird bio. has filed a patent for improved conditioning methods in hematopoietic stem cell transplantation and gene therapies. The method involves administering antibodies and endopeptidase to decrease stem cells and facilitate donor cell engraftment. GlobalData’s report on bluebird bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on bluebird bio, CAR-T cell based therapies was a key innovation area identified from patents. bluebird bio's grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Improved conditioning methods for hematopoietic stem cell transplantation
A patent application (Publication Number: US20240000847A1) describes a method for hematopoietic stem cell transplantation (HSCT) or HSC-based gene therapy in a subject. The method involves administering antibodies to ablate or decrease hematopoietic stem cells in the bone marrow, followed by an endopeptidase to degrade or inhibit the antibodies' effector function. Donor hematopoietic stem cells are then administered to the subject. The antibodies used in the method target specific antigens expressed on hematopoietic stem cells, and may be conjugated to cytotoxic agents. Additionally, the method includes the use of an endopeptidase, such as a cysteine protease, isolated from various bacterial species, to enhance the efficacy of the treatment.
Furthermore, the patent application details variations of the method, including the use of different antibodies, such as anti-CD47 or anti-SIRPa antibodies, and specific antigens targeted by the antibodies. The method also covers the administration of donor hematopoietic stem cells with genetic modifications or encoding therapeutic proteins for various diseases, including autoimmune diseases, hemoglobinopathies, and neurodegenerative diseases. Additionally, the method may involve the administration of HSC mobilization agents or chemotherapeutic agents to enhance the treatment's effectiveness. Overall, the patent application outlines a comprehensive approach to hematopoietic stem cell transplantation and gene therapy, offering potential advancements in the field of regenerative medicine and personalized treatment strategies for a range of diseases.
To know more about GlobalData’s detailed insights on bluebird bio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
